NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.44 +0.42 (+0.54%) GOLD FUTURES
2,362.50 +2.60 (+0.11%) DOW
39,558.11 +126.60 (+0.32%) Bitcoin GBP
48,953.14 -930.27 (-1.86%)
Theratechnologies Inc. (THTX)
After hours:
| Previous close | 1.1700 |
| Open | 1.2200 |
| Bid | 1.2600 x 400 |
| Ask | 1.2800 x 100 |
| Day's range | 1.2200 - 1.3400 |
| 52-week range | 0.8800 - 4.2000 |
| Volume | |
| Avg. volume | 32,870 |
| Market cap | 57.935M |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings date | 10 Jul 2024 - 15 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.67 |
GlobeNewswireTheratechnologies Reports on its Annual Meeting of Shareholders
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for
- GlobeNewswire
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and pharmacoki
ZacksTheratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
